Volume 96 Issue 1 | p. 13 | Concentrates
Issue Date: January 1, 2018

Boehringer options Autifony compounds

Department: Business
Keywords: Pharmaceuticals, Autifony, schizophrenia, neuroscience

Boehringer Ingelheim will pay nearly $30 million up front for the option to acquire Autifony Therapeutics’ voltage-gated potassium channel modulator platform. The pact includes AUT00206, currently in a Phase II study to treat schizophrenia. Autifony was spun off of GlaxoSmithKline in 2011 to develop modulators of Kv3 voltage-gated potassium channels, which allow neurons to fire with precision. Its compounds are also being studied as treatments for hearing disorders and rare neurological disorders such as fragile X syndrome.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment